Pacira BioSciences, Financials
| PCRX Stock | USD 17.38 0.35 2.06% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.5 | 5.237 |
|
|
The essential information of the day-to-day investment outlook for Pacira BioSciences, includes many different criteria found on its balance sheet. An individual investor should monitor Pacira BioSciences,'s cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Pacira BioSciences,.
Net Income |
|
Pacira | Select Account or Indicator |
Understanding current and past Pacira BioSciences, Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Pacira BioSciences,'s financial statements are interrelated, with each one affecting the others. For example, an increase in Pacira BioSciences,'s assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Pacira BioSciences,'s accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pacira BioSciences,. Check Pacira BioSciences,'s Beneish M Score to see the likelihood of Pacira BioSciences,'s management manipulating its earnings.
Pacira BioSciences, Stock Summary
Pacira BioSciences, competes with Phibro Animal, Dr Reddys, Collegium Pharmaceutical, Prestige Brand, and HUTCHMED DRC. Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida. Pacira Pharm operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 697 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US6951271005 |
| CUSIP | 695127100 |
| Location | New Jersey; U.S.A |
| Business Address | 5401 West Kennedy |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.pacira.com |
| Phone | 813 553 6680 |
| Currency | USD - US Dollar |
Pacira BioSciences, Key Financial Ratios
| Return On Equity | -0.11 | ||||
| Profit Margin | (0.13) % | ||||
| Operating Margin | 0.13 % | ||||
| Price To Sales | 1.13 X | ||||
| Revenue | 674.98 M |
Pacira BioSciences, Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 831.1M | 1.3B | 2.1B | 1.7B | 1.6B | 1.7B | |
| Other Current Liab | 18.2M | 85.7M | 127.6M | 80.7M | 64.2M | 41.2M | |
| Other Liab | 21.5M | 17.4M | 77.6M | 37.8M | 43.5M | 24.9M | |
| Net Debt | 273.7M | 441.2M | 543.3M | 659.3M | 432.7M | 454.4M | |
| Retained Earnings | (399.4M) | (253.9M) | (211.9M) | (148.8M) | (106.8M) | (112.1M) | |
| Accounts Payable | 12.8M | 10.4M | 10.5M | 15.2M | 15.7M | 10.4M | |
| Cash | 78.2M | 100.0M | 585.6M | 104.1M | 153.3M | 117.4M | |
| Other Assets | 971K | 290.1M | 153.4M | 160.3M | 1.0 | 0.95 | |
| Long Term Debt | 306.0M | 313.0M | 674.5M | 655.8M | 513.8M | 539.5M | |
| Net Receivables | 47.5M | 53.0M | 96.3M | 98.4M | 105.6M | 110.8M | |
| Inventory | 58.3M | 64.7M | 98.6M | 96.1M | 104.4M | 109.6M | |
| Other Current Assets | 10.8M | 12.3M | 29.4M | 15.2M | 21.5M | 22.6M | |
| Total Liab | 476.1M | 654.8M | 1.3B | 906.2M | 704.3M | 396.5M | |
| Total Current Assets | 408.6M | 651.6M | 866.0M | 498.3M | 510.0M | 331.8M | |
| Short Term Debt | 4.9M | 157.1M | 382.6M | 51.9M | 17.4M | 16.6M | |
| Common Stock | 42K | 44K | 45K | 46K | 52.9K | 35.1K | |
| Net Tangible Assets | 151.0M | 423.6M | (38.7M) | 71.2M | 81.9M | 77.8M | |
| Long Term Debt Total | 276.2M | 290.6M | 306.0M | 313.0M | 360.0M | 240.7M | |
| Capital Surpluse | 709.7M | 754.0M | 873.2M | 942.1M | 1.1B | 685.2M |
Pacira BioSciences, Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 23.6M | 25.7M | 31.8M | 40.0M | 20.3M | 15.8M | |
| Total Revenue | 421.0M | 420.8M | 541.5M | 666.8M | 675.0M | 708.7M | |
| Gross Profit | 314.3M | 303.5M | 401.3M | 467.5M | 490.3M | 514.8M | |
| Operating Income | 38.1M | 46.4M | 131.1M | 60.0M | 87.7M | 92.1M | |
| Ebit | 38.1M | 51.5M | 89.9M | 53.3M | 87.3M | 91.7M | |
| Research Development | 72.1M | 59.4M | 55.5M | 84.8M | 76.3M | 46.7M | |
| Ebitda | 43.8M | 71.4M | 118.5M | 144.8M | 162.9M | 171.0M | |
| Cost Of Revenue | 106.7M | 117.3M | 140.3M | 199.3M | 184.7M | 193.9M | |
| Income Before Tax | (10.7M) | 20.1M | 56.4M | 13.3M | 61.7M | 64.8M | |
| Net Income | (11.0M) | 145.5M | 42.0M | 15.9M | 42.0M | 44.1M | |
| Income Tax Expense | 268K | (125.4M) | 14.4M | (2.6M) | 19.7M | 20.7M | |
| Tax Provision | 268K | (125.4M) | 14.4M | (2.6M) | 2.9M | 3.1M | |
| Interest Income | 7.4M | 4.6M | 896K | 4.5M | 10.8M | 5.8M | |
| Net Interest Income | (16.3M) | (21.0M) | (30.9M) | (35.4M) | (17.2M) | (18.0M) |
Pacira BioSciences, Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Pacira BioSciences,. It measures of how well Pacira is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Pacira BioSciences, brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Pacira had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Pacira BioSciences, has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (8.0M) | (6.4M) | (4.5M) | 2.5M | (8.3M) | (7.9M) | |
| Change In Cash | (54.3M) | 21.7M | 485.6M | (481.4M) | 49.2M | 51.6M | |
| Free Cash Flow | 60.4M | 39.2M | 79.9M | 115.2M | 139.5M | 146.5M | |
| Depreciation | 19.6M | 19.9M | 28.5M | 91.5M | 75.6M | 79.4M | |
| Other Non Cash Items | 31.8M | 22.7M | 20.7M | 14.2M | 19.4M | 20.4M | |
| Capital Expenditures | 10.2M | 37.8M | 45.9M | 30.1M | 15.2M | 21.7M | |
| Net Income | (11.0M) | 145.5M | 42.0M | 15.9M | 42.0M | 44.1M | |
| End Period Cash Flow | 78.2M | 100.0M | 585.6M | 104.1M | 153.3M | 99.9M | |
| Investments | 984K | (239.8M) | 449.1M | (225.2M) | 80.4M | 84.4M | |
| Change Receivables | (6.0M) | (8.5M) | (5.5M) | (10.4M) | (9.4M) | (8.9M) | |
| Change To Netincome | 55.6M | (75.0M) | 54.8M | 57.6M | 66.2M | 69.5M |
Pacira Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pacira BioSciences,'s current stock value. Our valuation model uses many indicators to compare Pacira BioSciences, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pacira BioSciences, competition to find correlations between indicators driving Pacira BioSciences,'s intrinsic value. More Info.Pacira BioSciences, is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Pacira BioSciences,'s Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pacira BioSciences,'s earnings, one of the primary drivers of an investment's value.Pacira BioSciences, Systematic Risk
Pacira BioSciences,'s systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Pacira BioSciences, volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Pacira BioSciences, correlated with the market. If Beta is less than 0 Pacira BioSciences, generally moves in the opposite direction as compared to the market. If Pacira BioSciences, Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Pacira BioSciences, is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Pacira BioSciences, is generally in the same direction as the market. If Beta > 1 Pacira BioSciences, moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Pacira BioSciences, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Pacira BioSciences,'s growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Pacira BioSciences, growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Pacira BioSciences, November 21, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Pacira BioSciences, help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Pacira BioSciences,. We use our internally-developed statistical techniques to arrive at the intrinsic value of Pacira BioSciences, based on widely used predictive technical indicators. In general, we focus on analyzing Pacira Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Pacira BioSciences,'s daily price indicators and compare them against related drivers.
| Downside Deviation | 2.26 | |||
| Information Ratio | 0.1025 | |||
| Maximum Drawdown | 10.38 | |||
| Value At Risk | (3.21) | |||
| Potential Upside | 3.96 |
Additional Tools for Pacira Stock Analysis
When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.